ライフサイエンスコーパス: major bleeding

1 is strategies should have the lowest risk of major bleeding).

2 death, myocardial infarction, or stroke, or major bleeding).

3 t bleeding; 0.6% and 0.7%, respectively, for major bleeding).

4 , but some differences existed for stroke or major bleeding.

5 The safety outcome was major bleeding.

6 mplications in the care of ICU patients with major bleeding.

7 lly relevant bleeding, and 2.1% (n = 21) had major bleeding.

8 l increased spontaneous, but not procedural, major bleeding.

9 nts, without major vascular complications or major bleeding.

10 The primary outcome was major bleeding.

11 time likely constitute the best predictor of major bleeding.

12 ts with direct oral anticoagulant-associated major bleeding.

13 [95% CI, 1.04-1.55]) significantly increased major bleeding.

14 in- and direct oral anticoagulant-associated major bleeding.

15 thromboembolism without an increased risk of major bleeding.

16 was also associated with a moderate risk of major bleeding.

17 ence of such events, with a low incidence of major bleeding.

18 c and asymptomatic), pulmonary embolism, and major bleeding.

19 rdiovascular events and an increased risk of major bleeding.

20 mplications, including bowel perforation and major bleeding.

21 s were in-hospital mortality and in-hospital major bleeding.

22 arction, and stroke, although with increased major bleeding.

23 educed serious vascular events but increased major bleeding.

24 gnificantly higher adjusted risk of MACE and major bleeding.

25 A total of 146 neonates died or developed major bleeding.

26 s major bleeding and clinically relevant non-major bleeding.

27 botic events; the primary safety outcome was major bleeding.

28 ic embolism and 0.69 (95% CI, 0.66-0.71) for major bleeding.

29 utcomes were stroke or systemic embolism and major bleeding.

30 ll-cause mortality, reinfarction, stroke, or major bleeding.

31 0-35 days and the primary safety outcome was major bleeding.

32 The primary safety end point was major bleeding.

33 years old but does not increase the risk of major bleeding.

34 bolism, and the principal safety outcome was major bleeding.

35 iation of AC with mortality, intubation, and major bleeding.

36 The principal safety outcome was major bleeding.

37 nts was associated with an increased rate of major bleeding.

38 herapy was associated with a reduced risk of major bleeding.

39 y on Thrombosis and Haemostasis criteria for major bleeding.

40 concomitant therapy and a primary outcome of major bleeding.

41 ithout a significant increase in the risk of major bleeding.

42 as stroke and the primary safety outcome was major bleeding.

43 lic events without a significant increase in major bleeding.

44 lation Strategies) but increased the risk of major bleedings.

45 disease (p for interaction [p(int)] = 0.47), major bleeding 0.80 (95% CI: 0.70 to 0.91) in patients w

46 34; 95% CI, 0.22-0.51; P<0.001; I(2)=0%) and major bleeding (0.18% versus 0.9%; odds ratio, 0.22; 95%

47 embolism (1.58, 1.14-2.19, p=0.01), but less major bleeding (0.60, 0.47-0.75, p<0.0001) than those in

48 0.57-0.62]; P<0.001) and HAS-BLED score for major bleeding (0.69 [95% CI, 0.66-0.71] versus 0.62 [95

49 schemic stroke, 0.92 (95% CI, 0.75-1.12) for major bleeding, 0.54 (95% CI, 0.39-0.76) for cardiovascu

50 howed improved safety (relative risk [RR] of major bleeding, 0.61; 95% confidence interval [CI], 0.45

51 effusion requiring intervention (1.39%) and major bleeding (1.25%), whereas stroke (0.17%) and death

52 5% vs. 4.6%; p = 0.86), but a higher rate of major bleeding (1.4% vs. 1.0%; p = 0.03).

53 rmer did have a significantly higher rate of major bleeding (12% vs. 2%; p < 0.0001).

54 as 37.1%; mortality 18.9%; stroke 13.3%; and major bleeding 13.2% during a median follow-up of 632 da

55 dial infarction (2.9% versus 0.2%; P<0.001), major bleeding (14.0% versus 0.9%; P<0.001), blood trans

56 tract was the most common site of increased major bleeding (140 of 9,152 [1.5%] vs. 65 of 9,126 [0.7

57 43), fasciotomy (1.9% versus 8.9%; P<0.001), major bleeding (16.7% versus 21.0%; P<0.001), and transf

58 ational Society on Thrombosis and Hemostasis major bleeding (206 of 9,152 [2.3%] vs. 116 of 9,126 [1.

59 ational Society on Thrombosis and Hemostasis major bleeding (288 of 9,152 [3.1%] vs. 170 of 9,126 [1.

60 levant bleeding (4.8% vs. 2.9%, p = 0.34) or major bleeding (3.6% vs. 1.6%, p = 0.18).

61 ion and death at 1 year, but higher rates of major bleeding (43.3 versus 12.9 events/100 patient year

62 had a 50% higher risk of life-threatening or major bleeding (6.7% vs. 4.4%; p < 0.01).

63 tional Society on Thrombosis and Haemostasis major bleeding a secondary safety outcome.

64 For major bleeding, a tenecteplase-based regimen tended to b

65 Outcomes included major bleeding, access-site complications, in-hospital m

66 al clinical outcomes (mortality, stroke, and major bleeding) according to valve morphology (bicuspid

67 dney disease, anemia, coagulopathy, obesity, major bleeding, acute myocardial infarction, vascular co

68 Overall, 89 patients (2%) had major bleeding adjudicated by clinician review, with 27

69 Atrial fibrillation and major bleeding AEs (all grades) occurred in 7% and 5% of

70 lowed by P2Y12 inhibitor monotherapy reduces major bleeding after percutaneous coronary intervention

71 gher rates of procedural life-threatening or major bleeding after TAVR.

72 ntestinal (GI) bleeding, hospitalization for major bleeding, all-cause death, and composite outcome i

73 d in the subgroup of patients with confirmed major bleeding and baseline anti-factor Xa activity of a

74 Spontaneous major bleeding and bleeding associated with urgent invas

75 or monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients wit

76 The principal safety outcome was major bleeding and clinically relevant non-major bleedin

77 ted with fewer access-site complications and major bleeding and comparable technical success.

78 y, need for oral anticoagulation (OAC), TIMI major bleeding and drug intolerance.

79 Incidence rates (IRs) of major bleeding and hazard ratios were estimated overall,

80 Major bleeding and intracranial hemorrhage were similar

81 dels were used to estimate hazard ratios for major bleeding and major or clinically relevant nonmajor

82 ay mortality, irrespective of periprocedural major bleeding and vascular complications.

83 he PlaNet-2 data to predict baseline risk of major bleeding and/or mortality for all 653 neonates.

84 d of 25 x 109/L compared with 50 x 109/L for major bleeding and/or mortality in preterm neonates (7%

85 venous thromboembolism, 1.27 (0.92-1.74) for major bleeding, and 1.34 (1.19-1.51) for minor bleeding.

86 at higher risk for stroke/systemic embolism, major bleeding, and all-cause death than the standard-do

87 ay event rates per 100 patients for MI, CVD, major bleeding, and all-cause hospitalization were simil

88 =0.021) but a similar risk of death, stroke, major bleeding, and all-cause hospitalization.

89 n (MI), acute cerebrovascular disease (CVD), major bleeding, and all-cause hospitalization.

90 comes were recurrent venous thromboembolism, major bleeding, and all-cause mortality during 12 months

91 per patient-year for stroke of any severity, major bleeding, and gastrointestinal hemorrhage were low

92 or systemic embolism, intracranial bleeding, major bleeding, and hospitalization in patients undergoi

93 Of these, seven (11%) had major bleeding, and three of these also required circuit

94 For major bleeding, apixaban had a better safety profile tha

95 Patients with major bleeding are commonly admitted to the ICU.

96 , but the results for pulmonary embolism and major bleeding are highly uncertain.

97 Myocardial Infarction (TIMI) classification; major bleeding as defined by the International Society o

98 nary embolism, fatal pulmonary embolism, and major bleeding as secondary endpoints.

99 Major bleeding (as defined by the Bleeding Academic Rese

100 and targeting of modifiable risk factors for major bleeding, as well as the application of decision r

101 ty outcome, major or clinically relevant non-major bleeding (assessed in participants who received >=

102 In patients with acute major bleeding associated with the use of a factor Xa in

103 Major bleeding at 1 year occurred in 7.2% DCS patients a

104 s, or hospitalization for heart failure), or major bleeding at 12 months.

105 me of death, major cardiovascular events, or major bleeding at 12 months.

106 ed and outcomes including death, stroke, and major bleeding at 30 days and 1 year were compared by OA

107 rential relationship between aspirin use and major bleeding based on aspirin use in the 7 days prior

108 Safety outcomes included major bleeding, blood transfusion, and hospitalization f

109 o fibrinolytic therapy increased the risk of major bleeding by 1.27-8.82-times compared with accelera

110 after PCI significantly reduced the risk of major bleeding by 40% compared with dual antiplatelet th

111 ents (myocardial infarction, amputation, and major bleeding) by 12 months postrandomization, all P<0.

112 econdary outcomes (safety outcomes) included major bleeding, clinically relevant non-major bleeding (

113 included the composite of recurrent VTE and major bleeding, clinically relevant nonmajor bleeding (C

114 h CAT though carry an increased risk for non-major bleeding compared to standard of care, LMWH.

115 varoxaban was associated with higher risk of major bleeding compared with apixaban.

116 s thromboembolism without increasing risk of major bleeding compared with placebo or standard care in

117 of death, myocardial infarction, stroke, or major bleeding compared with platelet inhibition only (a

118 varoxaban plus aspirin combination increased major bleeding compared with the aspirin alone group (77

119 therapy was associated with reduced risk for major bleeding compared with triple therapy (risk differ

120 0.71-0.94) significantly reduced the risk of major bleeding compared with usual warfarin care.

121 that had preference for rivaroxaban had more major bleeding: compared with patients treated in facili

122 igher adjusted risk of in-hospital death and major bleeding complications, although study interpretat

123 Selatogrel was well tolerated, without major bleeding complications.

124 uded major bleeding, clinically relevant non-major bleeding (CRNMB), and all bleeding (major bleeding

125 on-major bleeding (CRNMB), and all bleeding (major bleeding + CRNMB).

126 ction, definite stent thrombosis, stroke, or major bleeding defined according to Platelet Inhibition

127 The primary bleeding outcome was any major bleeding (defined by the individual studies).

128 The principal safety outcome was major bleeding, defined according to the Thrombolysis in

129 Major bleeding, defined as hospitalization or emergency

130 The incidence of TIMI major bleeding did not differ significantly between the

131 th from any cause, myocardial infarction, or major bleeding during 180 days of follow-up.

132 osite of recurrent venous thromboembolism or major bleeding during the 12 months after randomization,

133 For major bleeding, edoxaban 60 mg (0.80, 0.71-0.90), edoxab

134 A new major bleeding episode or death occurred in 26% of the i

135 The main safety outcome was a major bleeding episode.

136 t for a lower number of life-threatening and major bleeding episodes in the rivaroxaban arms versus t

137 The rate of major bleeding episodes was higher with apixaban than wi

138 eported that approximately three-quarters of major bleeding episodes were of mild or moderate intensi

139 1,874 unique patients (19.7%) experienced a major bleeding event.

140 m (HR 0.37 [95% CI 0.24-0.55]; p<0.0001) and major bleeding events (0.54 [0.37-0.82]; p=0.0031).

141 e (4 vs 3 d; p < 0.01), as well as increased major bleeding events (41% vs 18%; p < 0.01).

142 al artery emboli, were determined as well as major bleeding events (BARC >=3) and all-cause mortality

143 person-years of follow-up, 4442 persons had major bleeding events (of which 313 [7%] were fatal).

144 ary endpoints included safety (determined by major bleeding events [time-to-event analysis on the tre

145 risk of recurrent venous thromboembolism and major bleeding events between the two drugs are currentl

146 use was associated with an increased risk of major bleeding events compared with no aspirin (23.1 per

147 tion of recurrent venous thromboembolism and major bleeding events in patients with venous thromboemb

148 Major bleeding events most often occurred <=7 days follo

149 atients; and apixaban, 12886 patients), 4770 major bleeding events occurred during 447037 person-quar

150 Major bleeding events occurred in 2% of the patients (al

151 Major bleeding events occurred in 71 (1.7%) of 4139 pati

152 lations, and a 42% relative risk increase in major bleeding events was used for the 5-year number nee

153 tio [HR] 1.15, 95% CI 0.68 to 1.94; p=0.61); major bleeding events were similar between the groups (t

154 h of stay, longer duration of organ support, major bleeding events, and mortality.

155 mbolism and nonvalvular atrial fibrillation, major bleeding events, including gastrointestinal (GI) b

156 recurrence, and 3 of 203 (1.5%) experienced major bleeding events, with 2 (1.0%) reporting clinicall

157 erous scales exist for the classification of major bleeding events.

158 primary safety outcome was the incidence of major bleeding events.

159 ment of recurrent venous thromboembolism and major bleeding events.

160 Prespecified safety outcomes included major bleeding (fatal, critical, or clinically overt ble

161 dence of major adverse events-death, stroke, major bleeding, filter migration, CCA thrombus, or steno

162 Patients with anticoagulation-associated major bleeding had higher in-hospital mortality (adjuste

163 oagulants, patients with warfarin-associated major bleeding had increased length of stay and costs.

164 Patients with warfarin-associated major bleeding had longer median length of stay (11 vs 6

165 use was associated with an increased risk of major bleeding (hazard ratio [HR], 1.61 [95% CI, 1.11-2.

166 h CrCl 25 to 30 mL/min, apixaban caused less major bleeding (hazard ratio, 0.34 [95% CI, 0.14-0.80])

167 , which was associated with a higher risk of major bleeding (hazard ratio: 2.19; 95% confidence inter

168 zard ratio [HR], 0.57 [0.43-0.75]; P<0.001), major bleeding (HR, 0.51 [0.44-0.61]; P<0.001), and mort

169 a similar risk of stroke but a lower risk of major bleeding (HR, 0.57 [0.43-0.75]; P<0.001) and morta

170 76-0.93) and as safe as VKAs with respect to major bleeding (HR, 0.83; 95% CI, 0.69-1.01).

171 sk of stroke (HR, 0.69 [0.51-0.94]; P=0.02), major bleeding (HR, 0.84 [0.72-0.99]; P=0.04), and morta

172 ase (HR, 0.96; 95% CI, 0.65-1.41; P = 0.83), major bleeding (HR, 1.23; 95% CI, 0.76-1.99; P = 0.41),

173 D; p interaction [pint] = 0.26; and for less major bleeding, HR: 0.74; 95% CI: 0.53 to 1.02 in patien

174 tive incidence, 6.0%; 95% CI, 4.4% to 8.1%), major bleeding in 39 patients (12-month cumulative incid

175 olic events without significantly increasing major bleeding in acutely ill medical patients after dis

176 t no statistically significant difference in major bleeding in apixaban-treated patients.

177 on triple therapy experienced high rates of major bleeding in comparison with patients on dual thera

178 Major or clinically relevant non-major bleeding in participants who received >=1 dose occ

179 el for ischemic stroke/systemic embolism and major bleeding in patients with atrial fibrillation from

180 ight groups, with even greater reductions in major bleeding in patients with atrial fibrillation with

181 n on major adverse cardiovascular events and major bleeding in patients with or without a history of

182 Incidence of major bleeding in this patient group was also similar be

183 non-major bleeding was unrelated to age, but major bleeding increased steeply with age (>/=75 years h

184 The primary end point was the composite of major bleeding, INR of 4 or greater, venous thromboembol

185 guided dosing, reduced the combined risk of major bleeding, INR of 4 or greater, venous thromboembol

186 Safety outcomes included major bleeding, intracranial bleeding, fatal bleeding, a

187 < .001) and also higher risk of in-hospital major bleeding (intravascular microaxial LVAD [31.3%] vs

188 re >6 (IR 17.6/100 PYs) or with a history of major bleeding (IR 17.5/100 PYs).

189 The most frequent type of major bleeding is gastrointestinal, but intracranial hem

190 RR2HAGES improved their predictive value for major bleeding leading to improved clinical usefulness c

191 spirin compared with aspirin alone increased major bleeding, mainly from the GI tract.

192 a for the assessment of the effectiveness of major bleeding management.

193 The results of the pulmonary embolism and major bleeding meta-analyses are uncertain and no clear

194 The occurrence of stroke/thromboembolism, major bleeding, myocardial infarction, and all-cause mor

195 (13 interventions; n=15 555), and 19 in the major bleeding network (11 interventions; n=19 797).

196 lactic dose, 10-14 days) ranked first in the major bleeding network (odds ratio 0.08 [95% CrI 0.00-1.

197 interval: 0.52 to 1.00; p = 0.049), whereas major bleeding occurred in 0.27% and 0.18% of patients i

198 Major bleeding occurred in 0.4% of patients in the low-i

199 In the modified intention-to-treat analysis, major bleeding occurred in 10 patients (3.5%) in the api

200 TIMI major bleeding occurred in 111 (2.0%) of 5536 patients r

201 ISTH major bleeding occurred in 140 patients in the rivaroxab

202 Major bleeding occurred in 22 patients (3.8%) in the api

203 In this patient group, major bleeding occurred in 3/103 patients on apixaban (2

204 Major bleeding occurred in 36 patients (6.9%) in the edo

205 Major bleeding occurred in 54 (10.7%) and 56 (11.0%) in

206 During the treatment period, major bleeding occurred in 6 patients (2.1%) in the apix

207 Major bleeding occurred in 6 patients (6.3%) in the riva

208 TIMI major bleeding occurred in 62 patients in the rivaroxaba

209 Major bleeding occurred in 7 patients (1.4%) in the riva

210 Similarly, major bleeding occurred in 79 (3%) of 2474 patients with

211 Major bleeding occurred in 8 of 405 patients (2.0%) in t

212 ycardia, duration of mechanical ventilation, major bleeding, occurrence of acute kidney injury, need

213 Major bleeding occurs in 1.1% of patients treated with d

214 erapy was associated with increased odds for major bleeding (odds ratio, 1.20; 95% CI, 1.05-1.36; p =

215 arin group (1.1% and 1.0%, respectively, for major bleeding or nonmajor clinically relevant bleeding;

216 The first 3 months after a major bleeding or surgical procedure were excluded from

217 I, 0.98-1.72; P=0.06), with no difference in major bleeding (OR, 1.47; 95% CI, 0.39-5.63; P=0.57) wit

218 39-1.05) and weak evidence of an increase in major bleeding (OR, 1.66; 95% credible intervals, 0.89-3

219 no differences in the risk of acute MI, CVD, major bleeding, or all-cause hospitalization after treat

220 ces were identified for the risk of MI, CVD, major bleeding, or all-cause hospitalization when compar

221 lism, vascular death, myocardial infarction, major bleeding, or intracranial hemorrhage as an outcome

222 Cluster rank plot incorporating stroke and major bleeding outcomes indicates that some warfarin car

223 ndependently associated with higher rates of major bleeding ( P<0.001 for each).

224 or systemic embolism (p interaction = 0.26), major bleeding (p interaction = 0.25), and death (p inte

225 del, major vascular complications (P=0.044), major bleeding (P=0.041), and RBC transfusion (P=0.048)

226 e to warfarin, with additional reductions in major bleeding, particularly hemorrhagic stroke, and mor

227 64-1.00], P-interaction=0.59), but increased major bleeding (PCI: 3.3% versus 2.0%; HR, 1.72 [95% CI,

228 Among ICU patients admitted with major bleeding, pre-admission anticoagulation use was as

229 s, and the 5-year absolute risk increase for major bleeding ranged from <5% in 53% of patients to 15%

230 Very high major bleeding rates occurred among patients on triple t

231 The overall and major bleeding rates were 4.8% (95% CI, 2.9-7.3) and 2.3

232 ally ill, radiographically confirmed VTE and major bleeding rates were 7.6% (95% CI, 3.9-13.3) and 5.

233 Annualized major bleeding rates were similar across AF patterns (2.

234 ents in each treatment group who experienced major bleeding received platelets, clotting factors, or

235 usal relationship between choice of NOAC and major bleeding, relative risk with rivaroxaban was 1.89

236 Ischemic/embolic complications and major bleeding remain important and strongly correlate t

237 y and safety outcomes were recurrent VTE and major bleeding, respectively.

238 pared to LMWH, DOACs showed no difference in major bleeding risk (RR 1.31; 95% CI 0.78-2.18; p = 0.31

239 of ischemic events, and it did not decrease major bleeding risk as compared with conventional treatm

240 23 to 0.98; p = 0.039), whereas an increased major bleeding risk was observed among patients with per

241 sk score x proportional effect of aspirin on major bleeding risk) over 5 years.

242 nal hazards models were developed to predict major bleeding risk; participants were censored at the e

243 Conversely, the risks of major bleeding (RR, 1.36; 95% CI, 0.55-3.35) and CRNMB (

244 Aspirin was associated with a higher risk of major bleeding (RR: 1.5; 95% CI: 1.33 to 1.69), intracra

245 red with aspirin, rivaroxaban increased TIMI major bleeding similarly regardless of clopidogrel use (

246 zation because of heart failure) and safety (major bleeding, stroke, procedure-related myocardial inf

247 rm DAPT was associated with a higher risk of major bleeding than all other DAPT groups.

248 y advocated because of its increased risk of major bleeding that largely offsets its ischemic benefit

249 all-cause death, myocardial reinfarction, or major bleeding), the individual components of the primar

250 For major bleeding, the addition of vWF to HAS-BLED improved

251 amputation, fasciotomy, acute kidney injury, major bleeding, transfusion, vascular complications, len

252 farction, and the primary safety outcome was major bleeding using modified International Society of T

253 2)DS(2)-VASc score >6 or with a history of a major bleeding warrants careful consideration of such th

254 The IR for major bleeding was 10.2/100 PYs among patients receiving

255 Meanwhile, the rate of major bleeding was 4.0%, myocardial infarction 2.0%, mor

256 TIMI major bleeding was a driver of stop/switch actions and o

257 of death, myocardial infarction, stroke, or major bleeding was assessed 1 year after PCI and Cox reg

258 Major bleeding was defined as bleeding requiring hospita

259 Major bleeding was increased by 70%, but there was no in

260 interval [CI]: 0.67 to 1.22; p = 0.50), but major bleeding was more common in patients with liver di

261 Major bleeding was more frequent with rivaroxaban 2.5 mg

262 he risk of the composite of recurrent VTE or major bleeding was nonsignificantly lower with DOACs tha

263 The excess hazard for major bleeding was not different in participants with HF

264 th from any cause, myocardial infarction, or major bleeding was not lower among those who received bi

265 ho received ticagrelor, and the incidence of major bleeding was not significantly different between t

266 hat a strong association between aspirin and major bleeding was observed for recent initiators of asp

267 No major bleeding was recorded, and no patient died during

268 The incidence of ISTH major bleeding was significantly higher with rivaroxaban

269 The risk of major bleeding was similar across treatment groups.

270 f the most severe events in each scale, ISTH major bleeding was the most common (n=1289), followed by

271 The incidence of major bleeding was three per 100 person-years in the api

272 Risk of non-major bleeding was unrelated to age, but major bleeding

273 onist monotherapy, adjusted hazard ratios of major bleeding were 1.13 (95% CI, 1.06-1.19) for dual an

274 r (CV) death, MI, and stroke as well as TIMI major bleeding were analyzed at yearly landmarks (years

275 stroke or systemic embolic event (SSEE) and major bleeding were assessed stratified by history of li

276 npatient admissions for ischemic strokes and major bleeding were compared across the 3 drugs (rivarox

277 ks for ischemic stroke/systemic embolism and major bleeding were estimated without anticoagulation th

278 the risk of life-threatening, disabling, or major bleeding were higher with rivaroxaban (hazard rati

279 death, myocardial infarction, or stroke) and major bleeding were more frequent in those with renal dy

280 ences in the risks of ischemic end points or major bleeding were observed with midterm or short-term

281 n demonstrated a trend toward lower rates of major bleeding when compared with those with CrCl >30 mL

282 use significantly increased the risk for any major bleeding when compared with warfarin (hazard ratio

283 nd was associated with a similar risk of any major bleeding when compared with warfarin and dabigatra

284 ry end points were myocardial infarction and major bleeding, which constituted the net clinical benef

285 tive risks for thrombosis, any bleeding, and major bleeding with antiplatelet therapy compared with n

286 tional Society on Thrombosis and Haemostasis major bleeding with clopidogrel use >30 days than with a

287 We evaluated the risk of major bleeding with concomitant therapy compared with an

288 ons in MACE and mortality but with increased major bleeding with or without previous PCI.

289 hemorrhagic stroke) and bleeding (318 prior major bleeding), with CHA(2)DS(2)-VASc score >=5 in 49%,

290 TIMI (Thrombolysis in Myocardial Infarction) major bleeding, with International Society on Thrombosis

291 In patients having PCDT versus No-PCDT, major bleeding within 10 days occurred in 1.5% versus 0.

292 We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a

293 had a significantly higher rate of death or major bleeding within 28 days after randomization than t

294 The primary outcome was death or new major bleeding within 28 days after randomization.

295 es of symptomatic venous thromboembolism and major bleeding within 3 months after the procedure.

296 tional Society on Thrombosis and Haemostasis major bleeding within 365 days (hazard ratio, 3.20 [95%

297 ovascular disease, myocardial infarction, or major bleeding within 6 months after intravitreal anti-V

298 device related death or adverse events, and major bleeding within 72 hours after BEC directed therap

299 all-cause death, myocardial reinfarction, or major bleeding, within 180 days.

300 dence rates of thrombosis, any bleeding, and major bleeding without antiplatelet therapy ranged from